Acurx (ACXP) Pharmaceuticals announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect its proprietary technologies in the field of antimicrobials. To date, Acurx has obtained three U.S. patents, one Israeli patent, one Japanese patent, and now one Indian patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors, with other country-level filings in process.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx files to sell 8.4M shares of common stock for holders
- Optimistic Buy Rating for Acurx Pharmaceuticals Amidst Financial Challenges and Promising Ibezapolstat Data
- Strategic Phase 3 Trials and Unique Microbiome Effects Drive Buy Rating for Acurx Pharmaceuticals
- Acurx Pharmaceuticals Reports 2024 Results and Advances Trials
- Acurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress